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Background: New and clinically useful markers of cardiovascular risk are of essence in type 2 diabetes since
ischemic heart disease is a major cause of death in these patients.
Methods: We analyzed baseline data from 476 men and 244 women who participated in “Cardiovascular Risk
factors in Patients with Diabetes -a Prospective study in Primary care” study. All participants had type 2 diabetes
and were 55-66 years old at recruitment during year 2005 to 2008. Except for established traditional risk markers
for vascular disease, we also estimated vascular complications non-invasively by performance of carotid-femoral
pulse-wave velocity (PWV, with applanation-tonometry) and intima-media thickness of carotid arteries (IMT, with
B-mode ultrasound). Patients were followed for incidence of ischemic heart disease mortality and morbidity until
end of the year 2012, using the national Swedish Cause of Death and Hospitalization Registries.
Results: During the follow-up period of a median of 6 years 47 men and 10 women died or were hospitalized for
ischemic heart disease including myocardial infarction. Leptin levels were positively related to the hazard ratio (HR)
in men (HR for each log 10 unit 4.9, CI 1.99 to 11.8) and women (HR 11.5, CI 1.47 to 89.7). Leptin predicted ischemic
heart disease independently of age, HbA1c, BMI, systolic blood pressure and LDL-cholesterol/HDL-cholesterol ratio
(men: HR 12.9 CI 3.2-53, women: HR 19.9, CI 1.2-327) This finding of increased risk related to high leptin levels was
also statistically significant when carotid-femoral PWV and IMT were both added to the equations in men (hazard
ratio 9.2 CI 2.1-41).
Conclusions: Our data support the use of serum leptin in type 2 diabetes to add independent prognostic
information in terms of ischemic heart disease when compared with traditional cardiovascular risk factors. In the
men of the cohort this prognostic information was in addition also to data on IMT and PWV, two non-invasive
measurements of the extent of vascular disease. The power to detect a similar relationship in women was less
strong due to lower incidence of cardiovascular disease.
Trial registration: ClinicalTrials.gov: NCT01049737.
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New and clinically useful markers of risk are of essence
in high risk states such as type 2 diabetes mellitus. The
major cause of death in type 2 diabetes mellitus is cardio-
vascular disease. One of the strongest predictors of such
manifestations of arteriosclerosis is the pulse wave velocity
in aorta, which is a non-invasive measure of the degree of
arterial calcification [1]. Yet another non-invasive estima-
tion of the degree of vascular disease can be done by
evaluating the thickness of the intima and media of ca-
rotid arteries by ultrasound [2]. Both these clinical physio-
logical examinations are non-invasive and hence risk-free
to perform. However, both these measures of risk require
skilled personnel and the equipment needed also carries a
considerable cost. Leptin is a hormone that is secreted by
adipose tissue that regulates metabolism and reduces ap-
petite. Levels of leptin in humans are log-linearly in-
creased in relation to obesity [3] and lack of leptin induces
severe obesity, demonstrating that leptin signaling is ne-
cessary for normal feedback control of body weight [4].
The feedback information to the central nervous system
regarding adipose tissue size by leptin is influenced by so
called leptin resistance [5] which likely is a reason for poor
effect to reduce body weight with recombinant leptin in
humans [6]. Potential adverse effects of this hormone in-
cludes increased activity of the sympathetic nervous sys-
tem and of the adrenal glands to secrete corticosteroids
[7] and leptin thus not only increases metabolic rate but it
also elevates blood pressure according to experimental
studies [8-11]. Leptin also has immune-modulatory effects
and it has been suggested that this hormone links obesity
with inflammation and hence with cardiovascular disease
by such mechanisms [12-14].
Since leptin apparently interact with many of the fea-
tures of cardiovascular risk, such as blood pressure and
inflammation, it might be a useful marker of prognosis
that gives information that is independent of a cluster of
classical clinical risk factors. Thus we prospectively stud-
ied leptin levels in relation to ischemic heart disease in
middle aged patients with type 2 diabetes mellitus. In
summary we found that levels of leptin were positively
related to the hazard ratio (HR) of ischemic heart dis-
ease in both men and women and this was independ-
ently of age, HbA1c, BMI, systolic blood pressure and
LDL-cholesterol/HDL-cholesterol ratio.
Methods
We analyzed baseline data from 244 women and 476 men
who participated in a community-based cohort, CArdio-
vascular Risk factors in patients with DIabetes – a Pro-
spective study in Primary care, acronym CARDIPP, in
which serum leptin was measured at the baseline investi-
gation. This prospective observational study was launched
in November 2005 and recruitment of the participantswas completed in 2008. The patients all had type 2 dia-
betes mellitus and were between 55–66 years old when
they were consecutively recruited from 22 different pri-
mary health care centers in the counties of Östergötland
and Jönköping, Sweden. Detailed information about the
structure and results from CARDIPP has been described
previously [15]. The centres were located in different
demographic areas and differed in size. However, the
model of treatment and care of diabetes was organized
similarly and all the primary care centres adhered to the
same national guidelines of diabetes care. The size of
the cohort and age of participants was chosen to allow
collection of endpoint data within 6 years, when assuming
similar incidence of cardiovascular disease as in other co-
horts of diabetes in Sweden [16].Anthropometric measurements
Nurses dedicated to treatment of diabetes at the primary
health care centers measured height to the nearest cm
and weight to the nearest 0.1 kg with the patients wear-
ing light indoor clothing. Waist circumference was mea-
sured according to WHO’s recommendations with the
patient standing, after a regular expiration, to the nearest
cm, midway between the lowest rib and the iliac crest. A
standardized medical history was taken that included
medication, previous cardiovascular diseases and smok-
ing habits.Laboratory analyses
Blood was drawn in the morning after a 10 hour over-
night fast. Standard tests such as HbA1c, plasma glu-
cose and serum lipids were analyzed according to rou-
tines at the primary health care centers. The laboratory
analyses were performed at Department of Clinical
Chemistry at the Linköping University Hospital. Levels
of cholesterol, HDL and triglycerides were measured
with enzymatic methodology and spectrophotometry,
(Selectra E, Vital Scientific, Dieren, Netherlands). LDL
was calculated by Friedewalds formula: LDL = cholesterol -
HDL - 0.45 × fS/P-triglycerides. HbA1c was analyzed ac-
cording to the Swedish Mono-S HPLC, all HbA1c values
were converted to DCCT standard values using the for-
mula: HbA1c DCCT = 0.923 × HbA1c (Mono-S) + 1.345
(R2 = 0.998).
The Milliplex® MAP Gut Hormone Panel (Merck
Millipore, Billerica, MA, USA) designed for analysis
with Luminex®-technique (Luminex, Austin, TX, USA)
was used for analysis of leptin, in concordance with ac-
companying instructions. Total coefficient of variation
(intra + inter assay) for leptin was 11%. The leptin levels
were corrected for the inter-batch difference of control
samples in the 10 batches in total used in the Luminex
based analysis of the total cohort.
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Determination of pulse PWV was done at the Department
of Physiology, Linköping University Hospital, Linköping
and at the County Hospital Ryhov, Jönköping. Aortic PWV
was measured with applanation tonometry (SphygmoCor®
system, model MM3, AtCor Medical, Sydney, Australia)
over the carotid and femoral arteries. The aortic pulse wave
transit times were measured by electrocardiogram-guided
readings of the femoral arterial pulse waves, using the ca-
rotid arterial pulse wave as the reference site. The surface
distances were estimated from the suprasternal notch to
the carotid and femoral measurement sites, respectively.
PWV was calculated by dividing the surface distance with
the pulse wave transit time yielding m × s-1.
Intima-media thickness of the carotid arteries (IMT)
were evaluated using B-mode ultrasound. A digital
ultrasound system (ATL HDI 5000, Bothell, WA, USA)
equipped with a broadband linear transducer (L12-5)
was used for scanning the carotid artery in the longitu-
dinal section. A 10 mm long section of the common ca-
rotid artery in the proximity of the carotid bulb was
selected to obtain mean lumen diameter and far wall
IMT. Three consecutive frozen images with focus on
lumen-intima echo and media-adventitia echo of the far
arterial wall were used. The digital B-mode images were
subsequently transferred to a computer with dedicated
software for off-line measurement of IMT (Artery Meas-
urement System II, Image and Data Analysis, Gothenburg,
Sweden). Calibration and subsequent measurement was
performed by manually tracing a cursor along the leading
edge of the intima-lumen echo of the near wall, leading
edge of the lumen- intima echo and media-adventitia echo
of the far wall. During analysis, the measurement window
was hidden for the reader and values were saved in a text
file. Mean values of IMT from both the right and the left
sides were used in all analyses.
Ischemic heart disease during follow-up
The participants were followed for occurrence of death or
hospitalization for myocardial infarction or ischemic heart
disease until December 31, 2012, by linkage with the
Swedish Cause of Death and Inpatient registries (The Na-
tional Board of Health and Welfare, Stockholm, Sweden)
using their unique personal identification numbers.
Ethics
All participants gave written informed consent prior to
participating in the study. The study, which complied
with the declaration of Helsinki, was approved by the
Regional Ethical Review Board in Linköping, Sweden.
Statistics
IBM SPSS statistics 21 and 22 (IBM corporation, Somers,
NY, USA) were used for statistics. In the main statisticalanalyses, Cox regression (Proportional Hazard Model)
was used. Pearson correlation coefficients were also calcu-
lated and statistical significance was defined as p < 0.05.
Leptin levels were log-transformed in calculations since
the distribution is skewed. Data were analyzed separately
in men and women since relationship between leptin and
obesity differs in genders [3]. The power of the study re-
garding an association between leptin and ischemic heart
disease was greater than 99%, both for males and females.
Results
Data on leptin in serum were successfully obtained in 246
women and 474 men in the cohort. There was strong a
positive linear relationship between leptin levels and BMI
(men: r = 0.631, women: r = 0.667, both p < 0.0001).
Women had higher leptin levels (p < 0.0001) also when
the comparison was corrected for BMI (p < 0.0001).
Table 1 shows baseline characteristics in men and
women analyzed separately. There were no statistically
significant correlations between leptin and age, duration
of diabetes or HbA1c levels in either gender (all p > 0.19
in men or women). In univariate analyses leptin levels cor-
related positively with PWV in men (r = 0.181, p < 0.0001)
but not with IMT (r = 0.06, p = 0.2), and these findings
were also apparent in women (leptin with PWV: r = 0.32,
p = 0.049, leptin with IMT: r = -0.10, p = 0.10). Leptin
levels were positively correlated with CRP (levels above
5 mg/l excluded, considered to be outliers) in men (r =
0.248, p < 0.0001, 72 excluded) and women (r = 0.187. p =
0.017, 69 excluded).
Cox regression analyses were performed separately in
men and women. No patients were lost to follow-up.
During the follow-up period of a median of 6 years 47
men and 10 women died or were hospitalized for ische-
mic heart disease including myocardial infarction. Of
these 57 incidents, 30 were due to angina, 21 of myocar-
dial infarction and the remaining 6 were deaths due to
ischemic heart disease. Serum leptin levels (crude) were
positively related to the composite endpoint in men
(hazard ratio for each log 10 unit of leptin 4.851, CI
1.987 to 11.84) and women (hazard ratio of 11.5 for
each log 10 leptin unit, CI 1.468 to 89.73). When enter-
ing major known cardiovascular risk factors to the Cox
regression leptin levels were positively related to ische-
mic heart disease in men, independently of age, HbA1c,
BMI, systolic blood pressure and LDL-cholesterol/HDL-
cholesterol ratio, smoking, and known duration of
diabetes (Table 2a). This finding of increased risk for is-
chemic heart disease related to leptin levels was also
statistically significant when carotid-femoral PWV and
IMT of the carotid arteries were added to these equa-
tions in men (Table 2b), while in women the relation-
ship was significantly related with the LDL/HDL ratio
(Table 2d).






Mean level Mean level
Age (years) 60.69 3.1 60.65 3.1
Diabetes duration (years) 7.1 6.36 7.4 5.7
Current smoker (%) 15.9 21.6
BMI (kg/m2) 29.7 4.2 *31.0 5.4
Waist circumference (cm) 105.2 11 *103.0 13
HbA1c (mmol/mol) 53.0 12 52.8 12
HbA1c (%, Mono-S) 6.09 1.1 6.06 1.12
Total cholesterol (mmol/l) 4.62 .92 4.95 1.03
HDL cholesterol (mmol/l) 1.23 .32 *1.40 .35
LDL cholesterol (mmol/l) 2.62 .75 *2.77 .86
LDL/HDL ratio 2.22 .73 *2.07 .78
Triglycerides (mmol/l) 1.81 1.2 1.78 .88
Systolic BP (mmHg) 136.9 16 137.4 17
Diastolic BP (mmHg) 80.7 10 *78.5 9.9
Antihypertensives (number
of drugs)
1.07 1.0 1.00 .93
Statin treatment (%) 53.0 58.0
OAD (number of drugs) .771 .75 .758 .70
Insulin treatment (%) 29.0 33.2
PWV (m/s) 10.39 2.1 10.27 2.0
IMT (mm) .755 .19 *0.702 .15
Leptin (ng/ml) 2561 2389 *7159 5654
*Denotes statistical difference between genders.
Abbreviations: BMI, body mass index; BP, blood pressure; HDL, high density
lipoprotein; IMT, intima-media thickness of carotid arteries; LDL, low density
lipoprotein; OAD, oral antidiabetic drugs; PWV, carotid-femoral pulse
wave velocity.
Data was missing in 54 patients for duration of diabetes; 13 patients about
smoking; 1 patient for BMI; 5 patients for waist circumferences; 10 patients for
HbA1c; 23 patients for cholesterol; 3 patients for BP; 20 patients for IMT and in
59 patients for PWV.
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of leptin in the lowest and highest tertiles in men and
women, after correction for the risk factors as in Table 2b
and d, respectively. When CRP was added to the ana-
lyses in Table 2b and d leptin levels were still signifi-
cantly related to ischemic heart disease in men while
CRP was not (leptin: p = 0.005, CRP: p = 0.96), however,
neither of these markers were independently related with
ischemic heart disease incidence in the corresponding
analyses in women (leptin: p = 0.68, CRP: p = 0.25).
Discussion
We found that high levels of leptin were related to in-
creased risks of ischemic heart disease independently of
traditional risk factors in men and that this prognostic
information also remained significant when carotid IMTand aortic PWV were both included in the Cox regression.
Importantly these analyses included BMI as a measure of
obesity and this implies that leptin gave additional infor-
mation independently of the degree of adiposity. This is in
line with the idea that leptin resistance, an insensitivity to
feedback signaling of adipose stores to the CNS, is linked
with increased risk for ischemic heart disease in patients
[17]. However, since our study did not include an inter-
vention aimed to affect leptin levels, this does not provide
definite proof of causality. Elevated levels of CRP have
been suggested to participate in induction of leptin resist-
ance by direct interaction with the leptin molecule [18].
The positive correlation between leptin and CRP in both
men and in women in our study is in line with such a the-
ory. Also leptin is a regulator of the sympathetic nervous
system with effects that, according to experimental stud-
ies, include increases of metabolic rate, angiogenesis and
arterial tone [9]. This could theoretically have impact on
ischemic heart disease incidence that goes beyond many
traditional markers of cardiovascular risk, including BMI
[19] which is in line with our findings in men with type 2
diabetes mellitus. High circulating leptin levels have earlier
been reported to be associated with diabetes incidence
and also with development of other components of the
metabolic syndrome [20]. However, leptin levels were not
found to be related to cardiovascular morbidity and mor-
tality in a study of non-diabetic elderly people [21].
In a study of patients with type 2 diabetes mellitus by
Brennan et al. leptin levels were reported not to be re-
lated to cardiovascular disease in 1194 women that were
followed for 12 years [22]. This finding was in contrast
to our data which do support prognostic use of leptin in
serum when added to traditionally used risk factors, to
estimate risk for ischemic heart disease in women. How-
ever, statistical significance was lost in the women in our
trial when IMT and PWV were included in the equations.
It is possible that less efficient treatment of complications
in diabetes might have obscured specific actions of leptin,
not acting through traditional risk factors, in the study by
Brennan et al., since data were analyzed during 12 years
up to the year 2002 [22], i.e. ending 3 years before we
made our baseline investigation. In line with this LDL-
cholesterol levels were 3.4-3.7 mmol/l across quintiles of
leptin in the study by Brennan et al. while corresponding
mean value was 2.77 in the women in the study presented
herein. This is suggestive of more efficient lipid lowering
therapy in our study which has been a trend in treatment
of type 2 diabetes mellitus in general during the last dec-
ade [23]. It is also possible that age of participants is cru-
cial in analyses of the risks related to leptin since at higher
age obesity is not strongly linked with morbidity and mor-
tality. Indeed, the term “obesity paradox” has been applied
to the phenomenon that moderate obesity might even be
beneficial in older age [24]. Indeed, better prognosis in




Lower CI Higher CI P value
Men
2a
Age (years) .987 .882 1.106 .828
Diabetes duration (years) 1.034 .994 1.076 .098
Smoking (current, former,
never)
1.883 1.126 3.151 .016
BMI (kg/m2) .913 .822 1.014 .089
Systolic blood pressure
(mmHg)
1.030 1.010 1.049 .003
HbA1c (mmol/mol) .999 .973 1.027 .958
LDL/HDL-ratio 1.260 .810 1.961 .305
Serum leptin (log 10 of
ng/ml)
12.895 3.162 52.589 <0.001
2b
Age (years) .968 .861 1.089 .591
Diabetes duration (years) 1.034 .991 1.079 .127
Smoking (current, former,
never)
1.570 .913 2.700 .103
BMI (kg/m2) .946 .842 1.063 .349
Systolic blood pressure
(mmHg)
1.024 1.003 1.046 .028
HbA1c (mmol/mol) 1.001 .971 1.032 .947
LDL/HDL-ratio 1.189 .737 1.919 .478
IMT (mm) 2.839 .721 11.180 .136
PWV (m/s) .953 .800 1.134 .584
Serum leptin (log 10 of
ng/ml)
9.219 2.088 40.705 .003
Women
2c
Age (years) 1.073 .861 1.337 .530
Diabetes duration (years) 1.060 .963 1.166 .231
Smoking (current, former,
never)
1.190 .470 3.013 .713
BMI (kg/m2) .995 .854 1.159 .949
Systolic blood pressure
(mmHg)
.980 .932 1.030 .418
HbA1c (mmol/mol) 1.050 .992 1.110 .090
LDL/HDL-ratio 1.733 .789 3.804 .171
Leptin (log 10 of ng/ml) 19.9 1.205 327 .037
2d
Age (years) 1.118 .831 1.506 .461
Diabetes duration (years) 1.08 .958 1.219 .205
Smoking (current, former,
never)
1.18 .365 3.815 .783
BMI (kg/m2) .934 .739 1.181 .570
Table 2 a-d Hazard ratios for ischemic heart disease
during follow up (Continued)
Systolic blood pressure
(mmHg)
1.035 .967 1.107 .321
HbA1c (mmol/mol) 1.06 .990 1.143 .094
LDL/HDL-ratio 3.85 1.091 13.6 .036
IMT (mm) 57.913 .603 5563.346 .081
PWV (m/s) .515 .262 1.013 .055
Leptin (log 10 of ng/ml) 26.8 .432 1662 .118
Cox regression of ischemic heart disease incidence (Proportional Hazard
Model) in relation to leptin levels and traditional risk factors, with (2b and 2d)
or without (2a and 2c) addition of intima-media thickness of carotid arteries
and carotid-femoral pulse wave velocity. Table 2a and b are data for the men,
2c and 2d show data for the women.
Abbreviations: BMI, body mass index; HDL, high density lipoprotein; IMT,
intima-media thickness of carotid arteries; LDL, low density lipoprotein; PWV,
carotid-femoral pulse wave velocity.
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diabetes > 65 years of age has been demonstrated [25] and
patients in the study by Brennan et al. became older dur-
ing follow up [22] than those in our cohort.
In males the relationship between leptin and IHD was
independent of traditional risk factors which was in line
with earlier trials in men with high risk but not necessarily
restricted to type 2 diabetes [26-29]. However, a study of
patients which also included a large proportion of patients
with diabetes and renal impairment did not find an inde-
pendent relationship with cardiovascular events of leptin
when analyzed among many other cytokines [30]. We
acknowledge that we had no information about cytokines
such as adiponectin or macrophage migration inhibitory
factor as in the paper by Schöttker et al. [30] but we did
find leptin to be independently related to ischemic heart
disease also in combination with two specific measures of
arteriosclerosis, IMT and PWV. This might seem contra-
dictory if leptin indeed mainly relates to arteriosclerotic
disease per se. Potential explanation could be that PWV
and IMT do not capture all information about true bur-
den of arteriosclerosis. Another potential explanation is
that although IMT and PWV together carry much infor-
mation about arteriosclerosis in large vessels, we do not
gain much knowledge from these measures of risk for
plaque rupture which is the main cause of acute ischemic
heart disease and which is to a large extent dependent on
whether a plaque is vulnerable or stable [31]. Indeed, lep-
tin has been found to be related to endothelial dysfunction
in diabetes [32].
Strengths in our study include use of registry data with
high quality and in terms of mortality and morbidity in-
cidence no lost to follow-up. Weaknesses include a ra-
ther short follow-up time and consequently low rates of
mortality and morbidity. However the relatively short
follow-up period suggests clinical relevance insofar that















































Figure 1 Cox regression analyses of event free survival in relation to leptin levels. The dashed line represents the lower tertile and solid line the
higher tertile of leptin levels in men (a) hazard ratio 9.219, confidence interval from 2.088 to 40.705, p = 0.003 and women (b) hazard ratio 26.8
confidence interval from 0.432 to 1662, p = 0.118. Data are adjusted for age, known duration of diabetes, HbA1c, systolic blood pressure, smoking,
LDL/HDL- ratio, BMI, carotid-femoral PWV and carotid IMT.
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by frequent treatment with statins and antihypertensive
medications, and levels of HbA1c and blood pressures
were also generally close to targets recommended by
guidelines. Indeed, it is possible that our finding of an as-
sociation between circulating leptin and risk for ischemic
heart disease was statistically significant after correctionfor traditional risk factors in men and women was made
possible by reasonably good control of glycaemia, blood
pressure and cholesterol that increased the chance to de-
tect the risk related leptin, that might act through other
mechanisms than mediated by the traditional risk factors
that are known to the provider of care. The positive rela-
tionship between serum leptin levels and CRP, confirmed
Vavruch et al. Cardiovascular Diabetology  (2015) 14:62 Page 7 of 8in our study, is an example of such a risk factor that is not
targeted in routine clinic care, as of yet.
Conclusions
This prospective observational data support the use of
serum leptin for estimation of risk for ischemic heart
disease independently of traditional risk factors. In the
men serum leptin also provided information about risk
that was independent of two strong non-invasive markers
of cardiovascular disease, carotid IMT and carotid-femoral
PWV. The results of our study support further assessment
in larger cohorts of the role of measuring leptin levels as a
predictive marker if ischemic heart disease in the care of
patients with type 2 diabetes.
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